Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BYQLOVI vs DEHYDRATED ALCOHOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BYQLOVI (revumenib) is a menin inhibitor that binds to the menin protein, blocking its interaction with mixed lineage leukemia (MLL) fusion proteins and thus inhibiting leukemogenesis.
Dehydrated alcohol (ethanol) causes tissue necrosis by protein denaturation and cellular dehydration, leading to vascular thrombosis and ischemic infarction. It ablates nerve tissue by extracting lipids and precipitating proteins.
Treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A (KMT2A) gene translocation in adults and pediatric patients 1 year and older
FDA-approved for adjunctive therapy in the treatment of cystic thyroid nodules,Off-label: Neurolysis for celiac plexus block in pancreatic cancer pain,Off-label: Ablation of hepatocellular carcinoma,Off-label: Sclerotherapy for esophageal varices
BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is administered orally as a single tablet (50/200/25 mg) once daily with or without food.
Intravenous administration: 0.1-1 m L of sterile dehydrated alcohol (100% ethanol) injected directly into cystic lesions or tumors under imaging guidance. Maximum volume per injection: 1 m L, repeated up to 3 times per session depending on lesion size.
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in patients with normal renal function; prolonged in renal impairment.
2-4 hours in most individuals at zero-order kinetics; terminal half-life is concentration-dependent due to saturation of alcohol dehydrogenase. Clinically, elimination rate is constant at 15-20 mg/d L/hour in non-tolerant individuals.
Primarily metabolized by CYP3A4 and CYP2D6.
Primarily hepatic via alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH); minor metabolism via CYP2E1 at high concentrations.
Renal excretion of unchanged drug accounts for approximately 95% of elimination; fecal excretion is minimal (<5%).
Ethanol is primarily eliminated by hepatic metabolism (90-98%) via alcohol dehydrogenase and aldehyde dehydrogenase, with 2-10% excreted unchanged in urine, breath, and sweat. Renal elimination is minor and variable.
Approximately 85% bound to serum albumin.
Negligible (<5%); no specific binding proteins.
Volume of distribution is about 0.6 L/kg, indicating distribution into total body water.
0.5-0.7 L/kg, approximating total body water. Higher in females due to lower lean body mass.
Oral bioavailability is approximately 80% (range 75–85%) under fasting conditions; food may reduce absorption.
Oral: ~80-100% due to rapid absorption from stomach and small intestine; IV: 100%.
Contraindicated in patients with estimated creatinine clearance (Cr Cl) <30 m L/min. No dose adjustment required for Cr Cl ≥30 m L/min.
No dosage adjustment required for renal impairment.
Not recommended in patients with severe hepatic impairment (Child-Pugh Class C). No dose adjustment required for mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.
No specific Child-Pugh-based adjustments; use with caution in severe hepatic dysfunction due to potential accumulation.
For adolescents aged ≥12 years and weighing ≥35 kg, administer one tablet (50/200/25 mg) orally once daily. Safety and efficacy not established in pediatric patients <12 years or <35 kg.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No specific dose adjustment recommended in elderly patients. Monitor renal function due to age-related decline.
No specific dose adjustment; use with caution due to age-related comorbidities and potential for increased sensitivity.
No FDA boxed warning reported.
No FDA boxed warning exists for dehydrated alcohol. However, it should only be administered by physicians experienced in injection techniques for specific indications due to risk of tissue necrosis and nerve damage.
Differentiation syndrome, which may be life-threatening or fatal; if suspected, initiate corticosteroids and hemodynamic monitoring.,QTc interval prolongation; monitor electrolytes and electrocardiograms.,Embryo-fetal toxicity.
Risk of tissue necrosis and sloughing if extravasation occurs,Neurological injury if injected near nerves (e.g., peripheral nerve damage, paralysis),Hypotension and bradycardia during celiac plexus block,Alcohol intoxication and CNS depression if absorbed systemically,Use with caution in patients with liver disease or diabetes mellitus
None reported.
Hypersensitivity to ethanol or any component of the formulation,Acute infection at the injection site,Uncorrectable coagulation abnormalities,Pregnancy (relative contraindication due to fetal alcohol spectrum disorders)
Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit as they inhibit CYP3A4 and can increase drug levels, leading to toxicity. No other known food interactions. Take with or without food, but consistent timing and fat content is recommended to maintain stable exposure.
No specific food interactions. However, avoid alcohol consumption for 24 hours post-procedure due to risk of additive CNS depression.
BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is contraindicated in pregnancy due to risk of neural tube defects (NTDs) observed with dolutegravir-containing regimens in first trimester exposure. In animal studies, no evidence of teratogenicity at clinically relevant exposures. Human data: insufficient for risk assessment; case reports of NTDs with bictegravir insufficient to rule out. First trimester: potential for NTDs, avoid unless benefit outweighs risk. Second/third trimester: limited data, no specific fetal risks identified, but use alternative if possible.
First trimester: Data limited; alcohol is a known teratogen causing fetal alcohol spectrum disorders. Increased risk of congenital anomalies (e.g., heart defects, microcephaly) with high systemic exposure. Second trimester: Continued risk for growth restriction and neurodevelopmental abnormalities. Third trimester: Risk of growth retardation, preterm birth, and neurobehavioral deficits. Avoid systemic use; local injection for nerve block or ablation has minimal systemic absorption but caution advised.
Breastfeeding not recommended during BYQLOVI therapy due to potential for HIV-1 transmission via breast milk and unknown effects in infants. Bictegravir excretion into human milk unknown; emtricitabine: M/P ratio ~0.6; tenofovir alafenamide: M/P ratio ~0.3 (tenofovir). Limited data: low levels may be excreted. HIV-positive mothers should not breastfeed to avoid transmission.
Alcohol is excreted into breast milk; M/P ratio approximately 1.0. Chronic ingestion can impair infant motor development. Dehydrated alcohol for therapeutic injection likely results in negligible systemic levels; however, avoid breastfeeding immediately after procedure. Advise discarding milk for 2-3 hours post-procedure.
No specific dosing adjustments recommended during pregnancy due to limited data. Pharmacokinetic studies in pregnancy are lacking. Bictegravir AUC may decrease in second and third trimester; clinical relevance unknown. Consider alternative antiretroviral regimens with established safety data in pregnancy (e.g., dolutegravir plus emtricitabine/tenofovir disoproxil fumarate).
No dose adjustment needed for localized injection; pharmacokinetics of ethanol unchanged in pregnancy. Avoid use as systemic agent; use alternative if possible.
BYQLOVI (bruton tyrosine kinase inhibitor) is indicated for chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia. Monitor for atrial fibrillation, hypertension, and bleeding risk. Administer with a full glass of water and do not crush or open capsules. Dose reduction may be needed with strong CYP3A4 inhibitors. Avoid concurrent use with warfarin or other anticoagulants if possible.
Absolute ethanol (dehydrated alcohol) is used for neurolysis in celiac plexus block for pancreatic cancer pain and for ablation of certain soft tissue lesions. Administer slowly to avoid local toxicity. Inadvertent intravascular injection can cause immediate pain and tissue necrosis. Use ultrasound or CT guidance for accurate placement. Monitor for hypotension, pain, and transient alcohol intoxication. Contraindicated in patients with bleeding disorders or local infection.
Take exactly as prescribed, with a full glass of water.,Do not open, break, or chew the capsules; swallow whole.,Avoid grapefruit, grapefruit juice, Seville oranges, and starfruit while on this medication.,Report any signs of bleeding (e.g., unusual bruising, black stools) or irregular heartbeat immediately.,Avoid activities that may cause injury due to increased bleeding risk.,Use effective contraception during treatment and for at least 1 month after the last dose.
You may feel a temporary burning sensation at the injection site.,This medication is used to block pain signals from certain nerves.,Avoid alcohol consumption for 24 hours after the procedure to prevent additive effects.,Report any severe pain, bleeding, or signs of infection to your healthcare provider.,You may experience temporary dizziness or lightheadedness after the injection.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BYQLOVI vs DEHYDRATED ALCOHOL, answered by our medical review team.
BYQLOVI is a Topical Retinoid that works by BYQLOVI (revumenib) is a menin inhibitor that binds to the menin protein, blocking its interaction with mixed lineage leukemia (MLL) fusion proteins and thus inhibiting leukemogenesis.. DEHYDRATED ALCOHOL is a Sclerosing agent that works by Dehydrated alcohol (ethanol) causes tissue necrosis by protein denaturation and cellular dehydration, leading to vascular thrombosis and ischemic infarction. It ablates nerve tissue by extracting lipids and precipitating proteins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BYQLOVI and DEHYDRATED ALCOHOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BYQLOVI is: BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is administered orally as a single tablet (50/200/25 mg) once daily with or without food.. The standard adult dose of DEHYDRATED ALCOHOL is: Intravenous administration: 0.1-1 m L of sterile dehydrated alcohol (100% ethanol) injected directly into cystic lesions or tumors under imaging guidance. Maximum volume per injection: 1 m L, repeated up to 3 times per session depending on lesion size.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BYQLOVI and DEHYDRATED ALCOHOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BYQLOVI is classified as Category C. BYQLOVI (bictegravir/emtricitabine/tenofovir alafenamide) is contraindicated in pregnancy due to risk of neural tube defects (NTDs) observed with dolutegravir-containing regimens i. DEHYDRATED ALCOHOL is classified as Category C. First trimester: Data limited; alcohol is a known teratogen causing fetal alcohol spectrum disorders. Increased risk of congenital anomalies (e.g., heart defects, microcephaly) wit. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.